Therapeutic and vaccine strategies against SARS-CoV-2: past, present and future
Published 2020 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Therapeutic and vaccine strategies against SARS-CoV-2: past, present and future
Authors
Keywords
-
Journal
Future Virology
Volume -, Issue -, Pages -
Publisher
Future Medicine Ltd
Online
2020-07-27
DOI
10.2217/fvl-2020-0137
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro
- (2020) Manli Wang et al. CELL RESEARCH
- Potential interventions for novel coronavirus in China: A systematic review
- (2020) Lei Zhang et al. JOURNAL OF MEDICAL VIROLOGY
- Outbreak of pneumonia of unknown etiology in Wuhan, China: The mystery and the miracle
- (2020) Hongzhou Lu et al. JOURNAL OF MEDICAL VIROLOGY
- Receptor recognition by novel coronavirus from Wuhan: An analysis based on decade-long structural studies of SARS
- (2020) Yushun Wan et al. JOURNAL OF VIROLOGY
- Baricitinib as potential treatment for 2019-nCoV acute respiratory disease
- (2020) Peter Richardson et al. LANCET
- Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding
- (2020) Roujian Lu et al. LANCET
- A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating person-to-person transmission: a study of a family cluster
- (2020) Jasper Fuk-Woo Chan et al. LANCET
- Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study
- (2020) Nanshan Chen et al. LANCET
- Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China
- (2020) Chaolin Huang et al. LANCET
- Coronavirus puts drug repurposing on the fast track
- (2020) Charlotte Harrison NATURE BIOTECHNOLOGY
- Therapeutic options for the 2019 novel coronavirus (2019-nCoV)
- (2020) Guangdi Li et al. NATURE REVIEWS DRUG DISCOVERY
- Evolution of the novel coronavirus from the ongoing Wuhan outbreak and modeling of its spike protein for risk of human transmission
- (2020) Xintian Xu et al. Science China-Life Sciences
- High expression of ACE2 receptor of 2019-nCoV on the epithelial cells of oral mucosa
- (2020) Hao Xu et al. International Journal of Oral Science
- Potent binding of 2019 novel coronavirus spike protein by a SARS coronavirus-specific human monoclonal antibody
- (2020) Xiaolong Tian et al. Emerging Microbes & Infections
- Analysis of therapeutic targets for SARS-CoV-2 and discovery of potential drugs by computational methods
- (2020) Canrong Wu et al. Acta Pharmaceutica Sinica B
- The spike glycoprotein of the new coronavirus 2019-nCoV contains a furin-like cleavage site absent in CoV of the same clade
- (2020) B. Coutard et al. ANTIVIRAL RESEARCH
- Transcriptional landscape of SARS-CoV-2 infection dismantles pathogenic pathways activated by the virus, proposes unique sex-specific differences and predicts tailored therapeutic strategies
- (2020) Paolo Fagone et al. AUTOIMMUNITY REVIEWS
- SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor
- (2020) Markus Hoffmann et al. CELL
- The use of anti-inflammatory drugs in the treatment of people with severe coronavirus disease 2019 (COVID-19): The Perspectives of clinical immunologists from China
- (2020) Wen Zhang et al. CLINICAL IMMUNOLOGY
- The mechanistic target of rapamycin (mTOR): Novel Considerations as an Antiviral Treatment and Possibilities for COVID-19
- (2020) Kenneth Maiese CURRENT NEUROVASCULAR RESEARCH
- SARS-CoV-2 Vaccines: Status Report
- (2020) Fatima Amanat et al. IMMUNITY
- New insights on the antiviral effects of chloroquine against coronavirus: what to expect for COVID-19?
- (2020) Christian A. Devaux et al. INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS
- Tocilizumab for the treatment of severe coronavirus disease 2019
- (2020) Rand Alattar et al. JOURNAL OF MEDICAL VIROLOGY
- Potential therapeutic agents against COVID-19
- (2020) Chih-Chia Lu et al. Journal of the Chinese Medical Association
- Considering BCG vaccination to reduce the impact of COVID-19
- (2020) Nigel Curtis et al. LANCET
- The COVID-19 vaccine development landscape
- (2020) Tung Thanh Le et al. NATURE REVIEWS DRUG DISCOVERY
- The FDA-approved drug ivermectin inhibits the replication of SARS-CoV-2 in vitro
- (2020) Leon Caly et al. ANTIVIRAL RESEARCH
- Clinical promise of next-generation complement therapeutics
- (2019) Dimitrios C. Mastellos et al. NATURE REVIEWS DRUG DISCOVERY
- Efficacy and Tolerability of Lopinavir/Ritonavir- and Efavirenz-Based Initial Antiretroviral Therapy in HIV-1-Infected Patients in a Tertiary Care Hospital in Beijing, China
- (2019) Bin Su et al. Frontiers in Pharmacology
- Favipiravir as a potential countermeasure against neglected and emerging RNA viruses
- (2018) Leen Delang et al. ANTIVIRAL RESEARCH
- BCG Vaccination Protects against Experimental Viral Infection in Humans through the Induction of Cytokines Associated with Trained Immunity
- (2018) Rob J.W. Arts et al. Cell Host & Microbe
- Complement Activation Contributes to Severe Acute Respiratory Syndrome Coronavirus Pathogenesis
- (2018) Lisa E. Gralinski et al. mBio
- Delayed oseltamivir plus sirolimus treatment attenuates H1N1 virus-induced severe lung injury correlated with repressed NLRP3 inflammasome activation and inflammatory cell infiltration
- (2018) Xuehong Jia et al. PLoS Pathogens
- Medicinal plants: a repository of antiviral metabolites
- (2017) Wajid Hussain et al. Future Virology
- Twenty-five years of mTOR: Uncovering the link from nutrients to growth
- (2017) David M. Sabatini PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- The Future of Immunotherapy: A 20-Year Perspective
- (2017) David C. Wraith Frontiers in Immunology
- Identification of Nafamostat as a Potent Inhibitor of Middle East Respiratory Syndrome Coronavirus S Protein-Mediated Membrane Fusion Using the Split-Protein-Based Cell-Cell Fusion Assay
- (2016) Mizuki Yamamoto et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Abelson Kinase Inhibitors Are Potent Inhibitors of Severe Acute Respiratory Syndrome Coronavirus and Middle East Respiratory Syndrome Coronavirus Fusion
- (2016) Christopher M. Coleman et al. JOURNAL OF VIROLOGY
- Coronaviruses — drug discovery and therapeutic options
- (2016) Alimuddin Zumla et al. NATURE REVIEWS DRUG DISCOVERY
- SARS and MERS: recent insights into emerging coronaviruses
- (2016) Emmie de Wit et al. NATURE REVIEWS MICROBIOLOGY
- The Effectiveness of Convalescent Plasma and Hyperimmune Immunoglobulin for the Treatment of Severe Acute Respiratory Infections of Viral Etiology: A Systematic Review and Exploratory Meta-analysis
- (2014) John Mair-Jenkins et al. JOURNAL OF INFECTIOUS DISEASES
- Mouse Dipeptidyl Peptidase 4 Is Not a Functional Receptor for Middle East Respiratory Syndrome Coronavirus Infection
- (2014) A. S. Cockrell et al. JOURNAL OF VIROLOGY
- A decade after SARS: strategies for controlling emerging coronaviruses
- (2013) Rachel L. Graham et al. NATURE REVIEWS MICROBIOLOGY
- Recombinant vaccines and the development of new vaccine strategies
- (2012) I.P. Nascimento et al. BRAZILIAN JOURNAL OF MEDICAL AND BIOLOGICAL RESEARCH
- Immunization with SARS Coronavirus Vaccines Leads to Pulmonary Immunopathology on Challenge with the SARS Virus
- (2012) Chien-Te Tseng et al. PLoS One
- Sirolimus Enhances the Magnitude and Quality of Viral-Specific CD8+ T-Cell Responses to Vaccinia Virus Vaccination in Rhesus Macaques
- (2011) A. P. Turner et al. AMERICAN JOURNAL OF TRANSPLANTATION
- mTOR as a multifunctional therapeutic target in HIV infection
- (2011) Ferdinando Nicoletti et al. DRUG DISCOVERY TODAY
- Evidence that TMPRSS2 Activates the Severe Acute Respiratory Syndrome Coronavirus Spike Protein for Membrane Fusion and Reduces Viral Control by the Humoral Immune Response
- (2011) I. Glowacka et al. JOURNAL OF VIROLOGY
- A Double-Inactivated Severe Acute Respiratory Syndrome Coronavirus Vaccine Provides Incomplete Protection in Mice and Induces Increased Eosinophilic Proinflammatory Pulmonary Response upon Challenge
- (2011) M. Bolles et al. JOURNAL OF VIROLOGY
- Potential use of rapamycin in HIV infection
- (2010) Marco Donia et al. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
- Number of Peripheral Blood Regulatory T Cells and Lymphocyte Activation at 3 Months After Conversion to mTOR Inhibitor Therapy
- (2010) D. San Segundo et al. TRANSPLANTATION PROCEEDINGS
- mTOR signaling at a glance
- (2009) M. Laplante et al. JOURNAL OF CELL SCIENCE
- Recent developments in low molecular weight complement inhibitors
- (2009) Hongchang Qu et al. MOLECULAR IMMUNOLOGY
- Inhibition of human immunodeficiency virus (HIV-1) infection in human peripheral blood leucocytes-SCID reconstituted mice by rapamycin
- (2008) F. Nicoletti et al. CLINICAL AND EXPERIMENTAL IMMUNOLOGY
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started